Affle (India) Limited vs Pfizer Limited
Put two companies head-to-head — source-verified financials and AI-analysed SWOT, together in one view.
Affle (India) Limited (Advertising technology) and Pfizer Limited (Pharmaceuticals) go head-to-head here — with source-verified financials and a full SWOT breakdown side by side on Nexvora Intelligence. On the figures reported, Pfizer Limited leads on Revenue (approx.) and Net profit (approx.).
Pfizer Limited leads on Revenue (approx.) and Net profit (approx.).
Choose Affle if you want exposure to mobile-first adtech, performance-based advertising, and growth markets, while accepting dependence on mobile ad budgets and competitive margin pressure. Choose Pfizer Limited if you prefer a pharmaceutical business backed by a strong global brand, regulatory expertise, and prescription/vaccine market presence, while accepting reliance on the parent pipeline and exposure to Indian price controls. The right choice depends on whether the buyer prioritizes adtech growth-market exposure or pharma brand, pipeline, and regulatory strengths.
Grounded in the verified figures and SWOT shown — guidance, not investment advice.
Head-to-head highlights
| Metric | Affle (India) Limited | Pfizer Limited | Basis |
|---|---|---|---|
| Revenue (approx.) | Approximately ₹1,800-1,900 crore | Approximately INR 2,000–2,500 crore | AI estimate |
| Net profit (approx.) | Approximately ₹280-320 crore | Approximately INR 400–700 crore | AI estimate |
An arrow marks the larger reported figure — a factual comparison, not a quality judgement. Verified figures come from official filings; AI estimates are approximate and unverified.
Affle (India) Limited
Advertising technology · India
Affle (India) Limited is an Indian advertising technology company focused on mobile marketing, user acquisition, and consumer intelligence. Its platforms help advertisers acquire, engage, and monetize users across mobile apps and digital channels, with a strong focus on India and other emerging markets.
Verified financials
No source-verified financials available.
Strengths
- Strong mobile-first adtech specialization
- Performance-based advertising model aligned with advertiser ROI
- Presence across India, Southeast Asia, and other growth markets
- Portfolio expanded through acquisitions such as Jampp, mediasmart, and RevX
Weaknesses
- Smaller scale than global platform giants
- Dependence on mobile advertising budgets
- Business complexity from multiple acquired platforms
- Exposure to margin pressure in competitive performance marketing
Opportunities
- Growth in mobile app ecosystems across emerging markets
- Rising advertiser demand for measurable performance marketing
- Expansion of AI-driven campaign optimization and consumer intelligence
- Cross-selling across acquired adtech platforms
Threats
- Privacy regulation and mobile identifier restrictions
- Competition from large walled-garden platforms
- Ad fraud and brand-safety concerns in digital advertising
- Macroeconomic slowdowns affecting advertising spend
Pfizer Limited
Pharmaceuticals · India
Pfizer Limited is the India-listed subsidiary/affiliate of Pfizer Inc., focused on marketing and distributing prescription medicines, vaccines, and healthcare products in India. Its portfolio spans vaccines, anti-infectives, cardiovascular, pain, women’s health, and specialty therapies.
Verified financials
No source-verified financials available.
Strengths
- Strong global Pfizer brand and scientific reputation
- Access to global product pipeline and regulatory expertise
- Established presence in Indian prescription and vaccine markets
- Portfolio includes differentiated and hospital-focused therapies
Weaknesses
- Dependence on parent-company pipeline and product priorities
- Exposure to Indian drug price controls and regulatory intervention
- Smaller scale than major domestic Indian pharma manufacturers
- Limited manufacturing footprint compared with integrated local competitors
Opportunities
- Rising demand for adult and pediatric vaccination
- Growth in specialty medicines and chronic disease therapies
- Expansion through hospital, institutional, and digital healthcare channels
- Potential introduction of more innovative Pfizer global products in India
Threats
- Intense competition from branded generics and domestic pharma firms
- Government price caps and reimbursement pressure
- Patent expiries and generic substitution
- Regulatory delays or import/manufacturing compliance issues
Frequently asked
Answered from source-verified figures on this page.
Affle (India) Limited vs Pfizer Limited: which company leads overall?
Pfizer Limited leads on Revenue (approx.) and Net profit (approx.).
Related market reports
Deep-dive intelligence on the markets these companies compete in.
Global Streaming & Connected TV Advertising Market — Intelligence Report
India Protein Industry Outlook — Intelligence Report
India Pharmaceutical Sector — Intelligence Report
Global Radiopharmaceuticals and Theranostics Market — Intelligence Report
AI Analyst
Insights and answers generated live from Affle (India) Limited vs Pfizer Limited's verified data. Modeled estimates — not investment advice.
- Affle (India) Limited operates in advertising technology in India, focusing on mobile marketing, user acquisition, and consumer intelligence.
- Affle’s platforms help advertisers acquire, engage, and monetize users across mobile apps and digital channels, with emphasis on India and other emerging markets.
- Pfizer Limited operates in India’s pharmaceuticals sector as the India-listed subsidiary or affiliate of Pfizer Inc.
- Notable: The two companies serve very different sectors, with Affle focused on digital advertising technology and Pfizer Limited focused on prescription medicines, vaccines, and healthcare products.